Heritage Pharmaceuticals makes leadership changes

Press enter to search
Close search
Open Menu

Heritage Pharmaceuticals makes leadership changes

Heritage Pharmaceuticals has new leadership. The East Brunswick, N.J.-based company tapped William Marth as CEO and president of North America and Europe, as well as its parent company, Heritage Pharma Holdings.

“I am very pleased to accept the role of president and chief executive officer of North America and Europe for the company during this exciting time,” Marth said. “The Emcure family, Mr. Samson, and the entire Heritage team have built a very successful company, and I look forward to continuing that tradition of success by executing on the current strategies, as well as identifying new opportunities to create additional value for Heritage.”

Marth also was appointed as a member of its board of directors and to its affiliates, Marcan Pharmaceuticals and EmCure Pharma UK's boards. Before joining Heritage, Marth was CEO and president of AMRI, CEO at Teva Pharmaceuticals and president of Teva Americas.

The company also appointed John Denman as president. Denman previously served as CEO and president of Renaissance SSA, where he oversaw the sterile products division.

“We are very pleased that Bill Marth and John Denman have decided to join our team. Bill is a recognized leader in the pharmaceutical industry who possesses invaluable expertise in formulating and executing strategic initiatives that have transformed pharmaceutical businesses,” Marvin Samson, chairman of the Heritage board of directors, said. “John is another great addition to the leadership team, having worked closely with Bill during his tenure with Teva.”

Related Topics